pyrazines has been researched along with Esophageal Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckley, AM; Clarke, N; Davern, M; Dunne, MR; Foley, EK; Kennedy, BN; Kennedy, SA; Lysaght, J; MacCarthy, F; Morrissey, ME; Nolan, A; O'Sullivan, J; O'Toole, D; Ravi, N; Reynolds, JV | 1 |
| Han, M; He, J; Li, J; Liu, C; Liu, Q; Yuan, H; Zhou, X | 1 |
| Chen, J; Fan, J; Wang, Y; Zhan, Q; Zhang, J; Zhang, L; Zhang, W; Zhao, D | 1 |
| Du, W; Gao, A; Guo, M; Herman, JG; Jiao, S; Wang, L; Zhang, L | 1 |
| Chen, K; Chen, W; Jin, J; Li, D; Mao, W; Su, D; Wu, J; Ying, L; Yu, H; Zhang, F; Zhang, N | 1 |
| Frangou, E; Hawkins, M; Holmes, J; Love, S; McGregor, N | 1 |
| Chen, KN; Dai, L; Dong, B; Fu, H; Kang, XZ; Liang, Z; Shen, LY; Shi, Q; Xiong, HC; Yan, WP; Yang, YB | 1 |
| Buckley, AM; Cannon, A; Dunne, MR; Kennedy, BN; Kennedy, SA; Lynam-Lennon, N; Maher, SG; O'Sullivan, J; Reynolds, AL; Reynolds, JV | 1 |
| Besanceney-Webler, C; Chen, EX; Cheng, J; Christos, P; Dilts, KT; Holloway, S; Keresztes, R; Lane, ME; Lin, J; Matulich, D; Ocean, AJ; Papetti, M; Schnoll-Sussman, F; Shah, MA; Sparano, JA; Ward, M; Wright, JJ; Xiang, J; Yantiss, RK | 1 |
| Boumelha, AJ; Dobrynin, G; Hammond, EM; Hawkins, MA; Ient, J; Leslie, RE; Leszczynska, KB; Maughan, T; Mukherjee, S; Senra, JM | 1 |
| Diehl, JA; Herlyn, M; Klein-Szanto, A; Lioni, M; Noma, K; Rustgi, AK; Smalley, KS; Snyder, A | 1 |
| Ackermann, H; Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J | 1 |
| Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N | 1 |
| Akagi, Y; Fujii, T; Kage, M; Kusukawa, J; Miyagi, M; Sayers, TJ; Seki, N; Shirouzu, K; Toh, U; Yamana, H | 1 |
| Bitterman, PB; Dahlberg, PS; Issaenko, OA; Polunovsky, VA | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP | 1 |
2 trial(s) available for pyrazines and Esophageal Neoplasms
| Article | Year |
|---|---|
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms | 2014 |
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2008 |
14 other study(ies) available for pyrazines and Esophageal Neoplasms
| Article | Year |
|---|---|
Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.
Topics: Adenocarcinoma; Biopsy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Esophageal Neoplasms; Glycolysis; Humans; Jurkat Cells; Metabolomics; Oxidative Phosphorylation; Oxygen Consumption; Phenotype; Pyrazines | 2020 |
ACP-5862 suppresses esophageal squamous cell carcinoma growth through inducing apoptosis via activation of endoplasmic reticulum stress and ROS production.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Endoplasmic Reticulum Stress; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Male; Mice, Inbred BALB C; Pyrazines; Reactive Oxygen Species | 2021 |
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Progression; Esophageal Neoplasms; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; Kaplan-Meier Estimate; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2021 |
Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Damage; DNA Repair; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; GPI-Linked Proteins; Heterografts; Humans; Male; Methylation; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Neuropeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; TOR Serine-Threonine Kinases; Tumor Burden | 2021 |
Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Interleukin-6; Interleukin-8; NF-kappa B; Phenylenediamines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2017 |
Challenges in implementing model-based phase I designs in a grant-funded clinical trials unit.
Topics: Clinical Trials, Phase I as Topic; Combined Modality Therapy; Esophageal Neoplasms; Humans; Isoxazoles; Maximum Tolerated Dose; Pyrazines; Research Design | 2017 |
The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cisplatin; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Pyrazines; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Pyrazinib (P3), [(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Phenols; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Small Molecule Libraries; Zebrafish | 2019 |
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Chemoradiotherapy; Esophageal Neoplasms; Humans; Isoxazoles; Mice; Pyrazines | 2016 |
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Esophageal Neoplasms; G2 Phase; Histones; Mice; Mice, Inbred NOD; Mitosis; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pyrazines; Remission Induction; Xenograft Model Antitumor Assays | 2008 |
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Esophageal Neoplasms; Fibroblasts; Humans; Mouth Neoplasms; Multiple Myeloma; Pyrazines | 2009 |
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cadherins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Epithelial Cells; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mesoderm; Neoplasm Invasiveness; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Spheroids, Cellular; Time Factors; Transfection; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation; Vorinostat | 2010 |
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Humans; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2010 |
Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; Esophageal Neoplasms; Eukaryotic Initiation Factor-4F; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Targeting; Humans; Phenotype; Phosphoproteins; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Proteolysis; Pyrazines; Receptor, ErbB-2; Repressor Proteins; RNA Caps; RNA, Messenger; RNA, Small Interfering; Sirolimus; Ubiquitin | 2012 |